Inhibition of angiogenesis decreases alveolarization in the developing rat lung.

To determine whether angiogenesis is necessary for normal alveolarization, we studied the effects of two antiangiogenic agents, thalidomide and fumagillin, on alveolarization during a critical period of lung growth in infant rats. Newborn rats were treated with daily injections of fumagillin, thalidomide, or vehicle during the first 2 wk of life. Compared with control treatment, fumagillin and thalidomide treatment reduced lung weight-to-body weight ratio and pulmonary arterial density by 20 and 36%, respectively, and reduced alveolarization by 22%. Because these drugs potentially have nonspecific effects on lung growth, we also studied the effects of Su-5416, an inhibitor of the vascular endothelial growth factor receptor known as kinase insert domain-containing receptor/fetal liver kinase (KDR/flk)-1. As observed with the other antiangiogenic agents, Su-5416 treatment decreased alveolarization and arterial density. We conclude that treatment with three different antiangiogenic agents attenuated lung vascular growth and reduced alveolarization in the infant rat. We speculate that angiogenesis is necessary for alveolarization during normal lung development and that injury to the developing pulmonary circulation during a critical period of lung growth can contribute to lung hypoplasia.

[1]  P. Soler,et al.  Intermittent positive-pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats. , 2015, The American review of respiratory disease.

[2]  T. L. Le Cras,et al.  Neonatal dexamethasone treatment increases the risk for pulmonary hypertension in adult rats. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[3]  T. L. Le Cras,et al.  Brief perinatal hypoxia increases severity of pulmonary hypertension after reexposure to hypoxia in infant rats. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[4]  R. Tuder,et al.  Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[5]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[6]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Eric C. Griffith,et al.  Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Waltenberger,et al.  VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). , 1998, Biochemical and biophysical research communications.

[9]  G. Mcmahon,et al.  Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. , 1998, Journal of medicinal chemistry.

[10]  W. Teague,et al.  Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia. , 1998, American journal of respiratory and critical care medicine.

[11]  D. Stewart,et al.  Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. , 1998, Circulation research.

[12]  D. Thibeault,et al.  Lung volume, pulmonary vasculature, and factors affecting survival in congenital diaphragmatic hernia. , 1998, Pediatrics.

[13]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[14]  R. D'Amato,et al.  Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. , 1997, Experimental eye research.

[15]  R Bicknell,et al.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.

[16]  D. Sawyer,et al.  Early fetal development of lung vasculature. , 1997, American journal of respiratory cell and molecular biology.

[17]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[18]  P. D’Amore,et al.  Vascular development: cellular and molecular regulation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[20]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[21]  A. Ullrich,et al.  Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.

[22]  T. Billiar,et al.  The effect of nitric oxide on fetal pulmonary artery smooth muscle growth. , 1995, The Journal of surgical research.

[23]  A. Uchida,et al.  Suppression of pulmonary metastasis by angiogenesis inhibitor TNP‐470 in murine osteosarcoma , 1995, International journal of cancer.

[24]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. N. Blanco,et al.  Alveolar size, number, and surface area: developmentally dependent response to 13% O2. , 1991, The American journal of physiology.

[26]  J. Tomashefski,et al.  Morphometric analysis of the lung in bronchopulmonary dysplasia. , 1991, The American review of respiratory disease.

[27]  T. Nakaki,et al.  Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. , 1990, European journal of pharmacology.

[28]  S. Young,et al.  Neonatal hyperoxia alters the pulmonary alveolar and capillary structure of 40-day-old rats. , 1990, The American journal of pathology.

[29]  L. N. Blanco,et al.  Alveolar dimensions and number: developmental and hormonal regulation. , 1989, The American journal of physiology.

[30]  D. Massaro,et al.  Short-term perinatal 10% O2 alters postnatal development of lung alveoli. , 1989, The American journal of physiology.

[31]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[32]  P. Burri,et al.  The postnatal development and growth of the human lung. II. Morphology. , 1987, Respiration physiology.

[33]  D. Massaro,et al.  Dexamethasone accelerates postnatal alveolar wall thinning and alters wall composition. , 1986, The American journal of physiology.

[34]  W M Thurlbeck,et al.  Human lung growth in late gestation and in the neonate. , 1984, The American review of respiratory disease.

[35]  W. Thurlbeck,et al.  Pulmonary hypoplasia in Down's syndrome. , 1982, The New England journal of medicine.

[36]  W. Thurlbeck,et al.  The radial alveolar count method of Emery and Mithal: a reappraisal 2--intrauterine and early postnatal lung growth. , 1982, Thorax.

[37]  W M Thurlbeck,et al.  The radial alveolar count method of Emery and Mithal: a reappraisal 1--postnatal lung growth. , 1982, Thorax.

[38]  L. J. Krovetz,et al.  The pulmonary vascular bed in children with Down syndrome , 1975 .

[39]  J. Emery,et al.  The Number of Alveoli in the Terminal Respiratory Unit of Man During Late Intrauterine Life and Childhood , 1960, Archives of disease in childhood.

[40]  K. Goss,et al.  Vascular endothelial growth factor gene expression in human fetal lung in vitro. , 1999, American journal of respiratory cell and molecular biology.

[41]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[42]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[43]  B. Schlinger.  Sexual differentiation of avian brain and behavior: current views on gonadal hormone-dependent and independent mechanisms. , 1998, Annual review of physiology.

[44]  H. Granger,et al.  Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. , 1996, The American journal of physiology.

[45]  D. Massaro,et al.  Formation of pulmonary alveoli and gas-exchange surface area: quantitation and regulation. , 1996, Annual review of physiology.

[46]  P. Minoo,et al.  Epithelial-mesenchymal interactions in lung development. , 1994, Annual review of physiology.

[47]  P. Burri,et al.  The postnatal development and growth of the human lung. I. Morphometry. , 1987, Respiration physiology.

[48]  G. Vawter,et al.  Bronchopulmonary dysplasia: a morphometric study with emphasis on the pulmonary vasculature. , 1984, Pediatric pathology.

[49]  J. Chi TPL?Krovetz.  The pulmonary vascular bed in children with Down syndrome. , 1975, The Journal of pediatrics.